Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
This study is looking at the best dose of Ceftriaxone, an antibiotic, for people hospitalized with community-acquired pneumonia (CAP) who are not in the intensive care unit. Researchers want to see if 1 gram of Ceftriaxone daily is as effective as 2 grams daily, but with fewer side effects. You might be able to join if you are 18 or older, have CAP, and are prescribed Ceftriaxone in the emergency department or within 72 hours of hospital admission. The main goal is to see if people achieve a clinical cure, meaning their pneumonia gets better, 120 days after starting the study. The current status of this study is unclear.
- Study design
- This is a pragmatic trial where 430 participants will be randomly assigned to receive either 1 gram or 2 grams of Ceftriaxone daily. There will be no direct patient contact.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be assessed for clinical cure 120 days after enrollment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Ceftriaxone Dosage for Non-Critical Community-Acquired Pneumonia
At a glance
Conditions
Where it's being run
2 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Clinical cureThe outcome will be assessed 120 days after enrollment
Defined by discharge from the hospital or antibiotic treatment for \< 8 days without any of the following: requirement for antibiotic escalation, admission to an intensive care unit, mechanical or noninvasive ventilation, readmission within 30 days, or mortality within 30 days